Anti-Hemophilic Factor VIII Concentrate from Canada
A plasma-derived or recombinant Factor VIII concentrate for preventing bleeding in hemophilia A patients. It is a blood fraction and immunological product under HTS 3002.90.52.50, prepared for therapeutic prophylactic use. Essential for clotting factor replacement therapy.
Duty Rate — Canada → United States
100%
Rate breakdown
9903.04.60100%Except as provided in heading 9903.04.61, patented pharmaceutical articles as provided for in subdivisions (c) and (d) of U.S. note 40 to this subchapter
9903.05.860%Articles provided for in subdivision (b) of U.S. note 52 to this subchapter
9903.05.900%Articles of aluminum, of steel or of copper or derivative aluminum or steel articles; passenger vehicles (sedans, sport utility vehicles, crossover utility vehicles, minivans and cargo vans) and light trucks; parts of passenger vehicles (sedans, sport utility vehicles, crossover utility vehicles, minivans and cargo vans) and light trucks; medium- and heavy-duty vehicles; parts of medium- and heavy-duty vehicles; wood products; patented pharmaceutical articles; and semiconductor articles, as provided in subdivision (f) of U.S. note 52 to this subchapter
Import Tips
• Provide coagulation activity units per vial and viral safety dossiers
• Ensure lyophilized form with reconstitution instructions for stability
• Avoid bulk plasma classification by specifying patient-ready dosing